Combination treatment versus LHRH alone in advanced prostatic cancer

Urologia Internationalis

Volumn 56, Issue , 1996, Pages 13-17

  Ferrari, Paolo ^a   Castagnetti, G ^a   Ferrari, G ^a   Baisi, B ^a   Dotti, A ^a  

^a Civic Hospital   (Italy)

Author keywords

Advanced prostatic cancer; Complete androgen blockade; LHRH analogue

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; BREAST DISEASE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FOLLOW UP; HOT FLUSH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYPROTERONE ACETATE; FLUTAMIDE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0029920385     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282863     Document Type: Article

References (30)

1. Labric F, Dupont A, Lacourcier Y. et al: New approach in the treatment of prostate cancer: Complete instead of only partial withdrawal of androgens. Prostate 1983:4:579-594.
2. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer, in de Vita VT, Heilman S. Rosenberg SA (eds): Important Advances in Oncology. Philadelphia. Lippincott, 1985. pp 2009-2044.
3. Labric F, Dupont A, Cusati L, Gomez JL, Mon-fette G: Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J Steroid Biochem 1990:37:943-950.
4. Maddv JA, Winternitz WW, Norrel H: Cryohy-pophvscctomy in the management of advanced prostatic cancer. Cancer 1971;28:322-328.
5. Murray R, Pitt P: Treatmcnt of advanced prostatic cancer resistant to conventional therapy with aminoglutcthimidc. Eur J Cancer Clin Oncol 1985:21:453-458.
6. MacFarlanc DA, Thomas LP, Harrison JH: A survey of total adrenalectomy in cancer of the prostate. Am J Surg 1960:99:562-572.
7. Drago JR, Santen RJ, Lipton A. et al: Clinical effect of aminoglutcthimide. medical adrenalectomy in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984:53: 1447-1450.
8. Harper ME, Pike A. Peeling WB. Griffiths K: Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974:60:117-125.
9. Moghissi E, Alban F, Horton R: Origin of androstandiol glucuronidc in men. J Clin Endocrinol Metab 1984;59:417-421.
10. De Peretti E, de Forest MG: Pattern of plasma dchydrocpiandrostcronc sulfate levels in humans from birth to adulthood. Evidence for testicular production. J Cell Endocrinol Metab 1978:47:572-577.
11. Belanger B, Belanger A, Labric F, Dupont A, Cusan L, Monfettc G: Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration. Unique importance of ext ratest icular androgen in men. J Steroid Biochem 1989:32:695-698.
12. Motta M: The endocrinological basis for hormonal therapy of prostate tumors: in Denis L (ed): The Medical Management of Prostate Cancer. II. Heidelberg, Springer. 1991. pp 27-44.
13. Griffiths K, Davies P, Eaton CL, Harper ME, Turkcs A, Peeling WB: Endocrine factors in the initiation, diagnosis, and treatment of prostatic cancer; in Voigt KD. Knabbe C (eds): Endocrine-Dependent Tumors. New York. Raven Press. 1991. pp 83-130.
14. Cunha GR, Donjacour AA, Cooke PS: The endocrinology and development biology of the prostate. Endocr Rev 1987;8:338-362.
15. Denis L: The Medical Management of Prostate Cancer. II. European School of Oncology Monograph Series. Heidelberg. Springer. 1990. p 110.
16. Worgul TJ, Santen RJ, Samojilik E. et al: Clinical and biochemical effect of aminoglutethim-ide in the treatment of advanced prostatie carcinoma. J Urol 1983:129:51-55.
17. Stanford E, Drago J, Rohner T, Santen R, Lip-ton A: Aminoglutcthimidc medical adrenalectomy for advanced prostatic carcinoma. J Urol 1976:115:70-74.
18. Sutfrin G, Coffey DS: Flutamide: Mechanism of action of a new nonsteroidal antiandrogcn. Invest Urol 1976; 13:429.
19. Sogani PC, Withmorc WF Jr: Experience with flutamide in previously untreated patients with advanced prostatic carcinoma. J Urol 1979; 122:640.
20. Norayana AS, Loenig SA, Culp DA: Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 1981:52:152-153.
21. Denis L, Kcuppens F, Robinson M. ct al: Complete androgen blockade: Data from an EORTC 3083 trial. Semin Urol 1990:8:166-174.
22. Boland G, Elhilalli M, Fradet J. et al: Total androgen blockade versus castration in metastatic cancer of the prostate; in Motta M, Serio M (eds): Hormonal Therapy of Prostatic Disease: Basie and Clinical Aspects. Bussum. Mediconi. 1988. pp 302-311.
23. Brisset JM, Bertagna C, Fiel K. et al: Total androgen blockade versus orchiectomy in stage D prostate cancer: in Klijn JGM (ed): Hormonal Manipulation of Cancer: Peptides. Growth Factors and New Steroidal Agents. New York. Raver Press. 1978. vol 18. pp 17-30.
24. Geller J, Albert J, Nachsteim DA, Loza DC: Advantage of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 1988:15:53-61.
25. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA: A controlled trial of lcuprolidc with and without flutamide in prostatic carcinoma. N Engl J Med 1989: 321:419-424.
26. Iverson P, Rasmussen F, Klarskov P, Christensen IJ. For the Danish Prostatic Cancer Group: Long-term results of Danish Prostatic Cancer Group Trial 86: Goserclin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993; 72(suppl):3851-3854.
27. Tyrrell CJ, Altwein JE, Klippel F. et al: Multi-center randomized trial comparing Zoladex with Zoladex plus flutamidcs in the treatment of advanced prostate cancer. Cancer 1993:71 (suppl):3878-3879.
28. Schulze H, Isaacs J, Senge T: Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J Urol 1987;137:909-911.
29. Denis L, Mettlin C: Conclusions from the American Cancer Society Workshop on Combined Castration and Androgen Blockade Therapy in Prostate Cancer. Atlanta. Ga. Sept 18-20. 1989. Cancer 1990:66:1086-1089.
30. Ferrari P, Castagneto G, Ferrari G, Pollastri CA, Dotti A: Combination treatment in Ml prostate cancer. Cancer 1993:72:3880-3885.